Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or “TMS”) and Spravato® (esketamine nasal spray) for the treatment of major depressive disorder (“MDD”) and other mental ...

Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder (MDD) by the Health Sciences Authority (HSA) back in Oct. 2020.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

Half of the study group met criteria for AUD in the past year and were evenly divided in terms of those who had or had not experienced a major depressive disorder in the past year. Individuals who ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

(A ketamine-derived drug called esketamine is approved for some people as part of treatment-resistant major depressive disorder in a certified clinical setting.) But doctors have developed a ...

The drug is available as an intravenous infusion or an intranasal product called Spravato (esketamine) and can be used alone or in combination with oral antidepressants. Other Treatments for Major ...